Phantomics is showcasing their recently FDA-approved automated cardiac MRI analysis AI diagnostic software, called "Myomics,"
Writer 최고관리자
Date 22-03-02 17:43
Views 890
Phantomics is showcasing their recently FDA-approved automated cardiac MRI analysis AI diagnostic software, called "Myomics," at the 37th International Medical Device and Hospital Equipment Exhibition (KIMES 2022) from March 10th to 13th. Myomics is an image diagnostic assistant software that automatically analyzes and provides information on biomarkers, such as relaxivity and left ventricular ejection fraction, which are special features that can indicate changes in cardiac function depending on cardiac disease. AI measures biomarkers that can be analyzed as numbers, similar to tumor size, directly from images. Relaxivity refers to the time it takes for hydrogen atoms in the body to absorb energy from electromagnetic waves in the strong magnetic field of an MRI and transfer that energy to the surrounding molecular environment (such as molecular structure and size). This is a measurable image-biomarker that reflects the molecular environment of substances and human tissues. Cardiac MRI can measure various quantitative indicators, including relaxivity, unlike X-rays or CT scans, and there is no radiation exposure. Through various clinical results that show that it is possible to diagnose at the level of a tissue examination with an MRI scan instead of surgery, cardiac MRI is becoming a sustainable alternative diagnostic method for tissue examinations. Myomics analyzes thousands of cardiac MRI images entirely automatically using AI technology, reducing the interpretation time that used to take more than 30 minutes to under three minutes, helping clinicians to quickly diagnose and determine treatment methods for ischemic heart disease, myocardial infarction, heart failure, etc. that are difficult to diagnose. Myomics recently received second-grade certification as a medical device and FDA approval from the Ministry of Food and Drug Safety. Phantomics is a teacher start-up founded by Professor Choi Byung-wook and CEO Kim Pan-ki of Yonsei University's Department of Radiology in 2019, aiming to provide companion diagnostic technologies that accurately diagnose the world's leading cause of death, cardiovascular disease, and screen expensive medical procedures in the approaching era of super-aging society.
Myomics Product Image